Mustang Bio Inc. [NASDAQ: MBIO] jumped around 0.01 points on Thursday, while shares priced at $3.20 at the close of the session, up 0.31%. The company report on October 8, 2020 that Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat.
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that initial Phase 1 data on MB-105, a PSCA-targeted CAR T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), will be presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat, which is being held October 20 – 23, 2020.
Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are pleased that City of Hope will be presenting initial data from the Phase 1 trial of MB-105 at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat. MB-105 is our CAR T cell therapy that is being studied for the potential treatment of prostate cancer. We look forward to continuing to progress this PSCA-targeted CAR T program.”.
Mustang Bio Inc. stock is now -21.57% down from its year-to-date (YTD) trading value. MBIO Stock saw the intraday high of $3.22 and lowest of $3.01 per share. The company’s 52-week high price is 4.85, which means current price is +79.78% above from all time high which was touched on 06/10/20.
Compared to the average trading volume of 1.36M shares, MBIO reached a trading volume of 2033651 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Mustang Bio Inc. [MBIO]?
B. Riley FBR have made an estimate for Mustang Bio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 20, 2019, representing the official price target for Mustang Bio Inc. stock. Previously, the target price had yet another raise to $7, while H.C. Wainwright analysts kept a Buy rating on MBIO stock.
The Average True Range (ATR) for Mustang Bio Inc. is set at 0.22 The Price to Book ratio for the last quarter was 2.03.
How has MBIO stock performed recently?
Mustang Bio Inc. [MBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.35. With this latest performance, MBIO shares dropped by -13.98% in over the last four-week period, additionally plugging by 7.74% over the last 6 months – not to mention a rise of 3.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MBIO stock in for the last two-week period is set at 44.08, with the RSI for the last a single of trading hit 42.99, and the three-weeks RSI is set at 46.91 for Mustang Bio Inc. [MBIO]. The present Moving Average for the last 50 days of trading for this stock 3.32, while it was recorded at 3.26 for the last single week of trading, and 3.27 for the last 200 days.
Mustang Bio Inc. [MBIO]: Deeper insight into the fundamentals
Return on Total Capital for MBIO is now -88.60, given the latest momentum, and Return on Invested Capital for the company is -90.90. Return on Equity for this stock declined to -105.37, with Return on Assets sitting at -79.84. When it comes to the capital structure of this company, Mustang Bio Inc. [MBIO] has a Total Debt to Total Equity ratio set at 30.06. Additionally, MBIO Total Debt to Total Capital is recorded at 23.12, with Total Debt to Total Assets ending up at 21.14. Long-Term Debt to Equity for the company is recorded at 27.15, with the Long-Term Debt to Total Capital now at 20.87.
Reflecting on the efficiency of the workforce at the company, Mustang Bio Inc. [MBIO] managed to generate an average of -$909,588 per employee.Mustang Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.80 and a Current Ratio set at 5.80.
Earnings analysis for Mustang Bio Inc. [MBIO]
With the latest financial reports released by the company, Mustang Bio Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBIO.
Insider trade positions for Mustang Bio Inc. [MBIO]
There are presently around $48 million, or 26.30% of MBIO stock, in the hands of institutional investors. The top three institutional holders of MBIO stocks are: JPMORGAN CHASE & CO with ownership of 1,934,462, which is approximately 21569.788% of the company’s market cap and around 1.70% of the total institutional ownership; BLACKROCK INC., holding 1,917,676 shares of the stock with an approximate value of $6.14 million in MBIO stocks shares; and VANGUARD GROUP INC, currently with $5.05 million in MBIO stock with ownership of nearly 14.201% of the company’s market capitalization.
Positions in Mustang Bio Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 50 institutional holders increased their position in Mustang Bio Inc. [NASDAQ:MBIO] by around 6,647,845 shares. Additionally, 17 investors decreased positions by around 539,286 shares, while 14 investors held positions by with 7,905,599 shares. The mentioned changes placed institutional holdings at 15,092,730 shares, according to the latest SEC report filing. MBIO stock had 19 new institutional investments in for a total of 3,020,313 shares, while 6 institutional investors sold positions of 289,660 shares during the same period.